Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 2:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 196,423 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: ALL Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparison of the Effect of 4th Generation Fluoroquinolones, Gatifloxacin and Moxifloxacin, on Epithelial Healing Following Photorefractive Keratectomy (PRK), A Substudy of: Initial Evaluation of Excimer Laser Keratorefractive Surgery in U.S. Army Personnel (WU # 2335-99)

NCT00414011
View directory record Official record
Conditions
Epithelium, Corneal
Interventions
Moxifloxacin, Gatifloxacin
Drug
Lead sponsor
Walter Reed Army Medical Center
Federal
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2005
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 17, 2013 · Synced Oct 24, 2026, 2:44 PM EDT
Completed Phase 3 Interventional

Evaluation of Efficacy and Safety of E004 in Children With Asthma

NCT01460511
View directory record Official record
Conditions
Asthma
Interventions
E004 (Epinephrine Inhalation Aerosol) HFA-MDI, Placebo-HFA
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
4 Years to 11 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
8
States / cities
Costa Mesa, California • Orange, California • Stockton, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 24, 2026, 2:44 PM EDT
Not yet recruiting Not applicable Interventional

Pivotal Study to Assess Safety and Performance of Neola®, a Novel Lung Monitoring Device for Neonates

NCT07060911
View directory record Official record
Conditions
RDS of Prematurity, Preterm Birth, Lung Diseases
Interventions
Lung monitoring with the Neola device
Device
Lead sponsor
Neola Medical Inc
Industry
Eligibility
1 Day to 44 Weeks
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Palo Alto, California • Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Oct 24, 2026, 2:44 PM EDT
Completed Phase 3 Interventional Results available

Efficacy & Safety of Abaloparatide-Solid Microstructured Transdermal System in Postmenopausal Women With Osteoporosis

NCT04064411
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
abaloparatide, abaloparatide solid microstructured transdermal system
Combination Product
Lead sponsor
Radius Health, Inc.
Industry
Eligibility
50 Years to 85 Years · Female only
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
77
States / cities
Birmingham, Alabama • Anchorage, Alaska • Glendale, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Oct 24, 2026, 2:44 PM EDT
Terminated No phase listed Observational

Frovatriptan and Menstrual Migraine

NCT01114711
View directory record Official record
Conditions
Frovatriptan, Menstrual Migraine
Interventions
Not listed
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 12, 2018 · Synced Oct 24, 2026, 2:44 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Resistance Exercise and Protein During Weight Loss

NCT03600311
View directory record Official record
Conditions
Weight Loss, Starvation
Interventions
Caloric Restriction, Post-Exercise Protein, Energy Balance, Post-Exercise Carbohydrate, Calcium and Vitamin D
Other · Dietary Supplement
Lead sponsor
University of Nebraska Lincoln
Other
Eligibility
19 Years to 30 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Oct 24, 2026, 2:44 PM EDT
Recruiting Phase 1 Interventional

Hyperpolarized Imaging in Diagnosing Participants With Glioma

NCT03739411
View directory record Official record
Conditions
Glioma
Interventions
Hyperpolarized Carbon C 13 Pyruvate, Magnetic Resonance Imaging, Radiation Therapy, Chemotherapy
Radiation · Procedure · Drug
Lead sponsor
Susan Chang
Other
Eligibility
19 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 24, 2026, 2:44 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Culturally Smart Relationships Study

NCT05391711
View directory record Official record
Conditions
Racism
Interventions
Culturally Smart Relationships
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
9 Years to 17 Years
Enrollment
813 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 24, 2026, 2:44 PM EDT
Completed No phase listed Observational

A Retrospective Multicenter Review to Evaluate the Performance of the Ion Endoluminal System in Sampling Pulmonary Lesions

NCT05160571
View directory record Official record
Conditions
Lung Cancer, Pulmonary Nodule
Interventions
Ion Endoluminal System
Device
Lead sponsor
Intuitive Surgical
Industry
Eligibility
18 Years and older
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Winchester, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 3, 2023 · Synced Oct 24, 2026, 2:44 PM EDT
Terminated Phase 2 Interventional Results available

Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer

NCT01871571
View directory record Official record
Conditions
Mucinous Adenocarcinoma of the Rectum, Signet Ring Adenocarcinoma of the Rectum, Stage IIA Rectal Cancer, Stage IIB Rectal Cancer, Stage IIC Rectal Cancer, Stage IIIA Rectal Cancer, Stage IIIB Rectal Cancer, Stage IIIC Rectal Cancer
Interventions
bevacizumab, oxaliplatin, leucovorin calcium, fluorouracil, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 24, 2026, 2:44 PM EDT
Completed Not applicable Interventional Results available

Use of Interferential Current (IFC) Therapy After Total Knee Arthroplasty

NCT04137731
View directory record Official record
Conditions
Osteo Arthritis Knee
Interventions
Interferential Current Therapy
Device
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 8, 2023 · Synced Oct 24, 2026, 2:44 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation

NCT04165031
View directory record Official record
Conditions
Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Cancer
Interventions
LY3499446, Abemaciclib, Cetuximab, Erlotinib, Docetaxel
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Indianapolis, Indiana • Middletown, New Jersey • Harrison, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2021 · Synced Oct 24, 2026, 2:44 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Connecting National Guard Service Members Through Education in Crisis Line Facilitation Training

NCT05405231
View directory record Official record
Conditions
Suicide
Interventions
Crisis Line Facilitation (CLF), Passive Implementation
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
538 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Oct 24, 2026, 2:44 PM EDT
Completed Phase 4 Interventional

Randomized Comparison of the Abbott WHITESTAR Signature System With Ellips Tranversal Ultrasound vs. the Alcon Infiniti With the Ozil Torsional Handpiece in Phacoemulsification: A Contralaterally-Controlled Trial

NCT01279031
View directory record Official record
Conditions
Cataracts, Astigmatism
Interventions
Abbott WHITESTAR Signature System with Ellips Transversal Ultrasound, Alcon Infiniti wiht the OZIL Torsional Handpiece
Device
Lead sponsor
Innovative Medical
Industry
Eligibility
21 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Jan 18, 2012 · Synced Oct 24, 2026, 2:44 PM EDT
Terminated Phase 2Phase 3 Interventional

Mindfulness Training Plus Oxytocin Effects on Smoking Behavior

NCT03819231
View directory record Official record
Conditions
Smoking, Smoking Cessation
Interventions
Oxytocin, Mindfulness, Saline Solution, Sham mindfulness
Drug · Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2024 · Synced Oct 24, 2026, 2:44 PM EDT
Completed Phase 2 Interventional Results available

Investigation of H01 in Adults With Pulmonary Hypertension Including Interstitial Lung Disease (The SATURN Study).

NCT05128929
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Hymecromone (H01), Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Oct 24, 2026, 2:44 PM EDT
Completed No phase listed Observational

Physiological Response to Exercise: Sensor Evaluation at Specified Exertions

NCT01229137
View directory record Official record
Conditions
Heart Failure
Interventions
SRD-1 conversion
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
14
States / cities
Jonesboro, Arkansas • Sacremento, California • Danbury, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2012 · Synced Oct 24, 2026, 2:44 PM EDT
Completed Phase 4 Interventional Results available

A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder

NCT00206102
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
quetiapine fumarate, risperidone
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,098 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
63
States / cities
Little Rock, Arkansas • Mabelvale, Arkansas • Morrilton, Arkansas + 60 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2013 · Synced Oct 24, 2026, 2:44 PM EDT
Completed Phase 2 Interventional Results available

Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT01718353
View directory record Official record
Conditions
Prostate Cancer Metastatic
Interventions
DOCETAXEL (XRP6976), CABAZITAXEL (XRP6258), Prednisone
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Male only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
14
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Indianapolis, Indiana + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Oct 24, 2026, 2:44 PM EDT
Recruiting Phase 2 Interventional

HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM

NCT06822972
View directory record Official record
Conditions
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Interventions
Selinexor 40 mg
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 24, 2026, 2:44 PM EDT
Completed Not applicable Interventional

e-SMART/EST HIV Telehealth Intervention

NCT05278572
View directory record Official record
Conditions
Hiv, Depression
Interventions
Stress Management and Relaxation Training/Expressive Supportive Therapy (SMART/EST)
Behavioral
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
55 Years to 99 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Oct 24, 2026, 2:44 PM EDT
Not yet recruiting Phase 3 Interventional

Multiparametric Ultrasound for the Diagnosis of Clinically Significant Prostate Cancer

NCT06024772
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
ultiparametric Magnetic Resonance Imaging, Perflutren lipid microsphere, Transrectal Ultrasound, Biopsy of Prostate
Procedure · Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older · Male only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 24, 2026, 2:44 PM EDT
Completed No phase listed Observational

Characterizing Recurrent Thromboembolism, Major Bleeding and All-Cause Death in Patients With Cancer-Associated Thromboembolism Treated With Rivaroxaban

NCT03214172
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Rivaroxaban (Xarelto, BAY59-7939)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Oct 24, 2026, 2:44 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Darunavir/Ritonavir and Rosuvastatin Pharmacokinetic Study

NCT00885495
View directory record Official record
Conditions
HIV Infections
Interventions
darunavir, ritonavir, rosuvastatin, rosuvastatin, darunavir, ritonavir
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 11, 2022 · Synced Oct 24, 2026, 2:44 PM EDT